GSK plc GSK NYSE

GSK plc (GSK) has shown moderate revenue growth over the past 3 years, expanding from $29.3B to $32.0B (average +2.9%/yr). Net income reached $5.6B, reflecting exceptional earnings expansion at +23.2%/yr on average. The net profit margin is 17.5%, which is high. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 72.5% (high), with a +5.1pp trend over the period. With a $119B market cap and MOAT composite score of 90/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (73/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 41-year history, the company was profitable in 41 of 41 years — a perfect long-term track record
• INCOME (70/100, Pass) — proves strong profitability and pricing power
• MOAT (90/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 64/100 with 4/7 criteria passed.